Literature DB >> 18706021

Statins as acute-stroke treatment.

Mitchell S V Elkind1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 18706021     DOI： 10.1111/j.1747-4949.2006.00061.x

Source DB:  PubMed          Journal:  Int J Stroke        ISSN： 1747-4930            Impact factor:   5.266


× No keyword cloud information.
  5 in total

1.  Short-term high-dose effect of lovastatin on thrombolysis by rt-PA in a human whole-blood in vitro clot model.

Authors:  Madhuvanthi A Kandadai; Jason Meunier; Christopher J Lindsell; George J Shaw; Mitchell S V Elkind
Journal:  Curr Neurovasc Res       Date:  2012-08       Impact factor: 1.990

Review 2.  3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases.

Authors:  Joshua Z Willey; Mitchell S V Elkind
Journal:  Arch Neurol       Date:  2010-09

3.  High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART).

Authors:  Mitchell S V Elkind; Ralph L Sacco; Robert B Macarthur; Ellinor Peerschke; Greg Neils; Howard Andrews; Joshua Stillman; Tania Corporan; Dana Leifer; Rui Liu; Ken Cheung
Journal:  Cerebrovasc Dis       Date:  2009-07-16       Impact factor: 2.762

4.  The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke.

Authors:  Mitchell S V Elkind; Ralph L Sacco; Robert B MacArthur; Daniel J Fink; Ellinor Peerschke; Howard Andrews; Greg Neils; Josh Stillman; Tania Corporan; Dana Leifer; Ken Cheung
Journal:  Int J Stroke       Date:  2008-08       Impact factor: 5.266

Review 5.  Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.

Authors:  Surojit Paul; Eduardo Candelario-Jalil
Journal:  Exp Neurol       Date:  2020-11-02       Impact factor: 5.330
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.